RESUMO
In the COVID-19 pandemic, there was an increase in consultations for precocious puberty. We aim to analyze differences in female puberty before and during the COVID-19 pandemic. A cross-sectional analytical study was designed at the Pediatric Endocrinology Clinic of the University Hospital of the Federal University of Maranhão in São Luis, Brazil. We included 55 girls with precocious puberty, 22 who started puberty during the pandemic and 33 who started puberty before the pandemic. Clinical, anthropometric, laboratory and imaging variables were compared between groups. Statistics were performed to determine if there was a statistical difference between the groups. Girls with puberty during the pandemic had higher Z-scores for weight (1.08 ± 1.29 versus 0.69 ± 0.83; p = 0.04), lower ovarian volume (1.88 ± 0.95 versus 3.15 ± 2.31; p = 0.01), and smaller differences between thelarche noticed by the parents and the diagnosis (6.63 ± 5.21 versus 12.15 ± 9.96; p = 0.02). The association between precocious puberty during the pandemic with higher Z-scores for weight, lower ovarian volume, and a reduction in the time between the perception of pubertal findings by parents and the diagnosis suggests the influence of the pandemic on the normal time of puberty.
Assuntos
COVID-19 , Puberdade Precoce , COVID-19/epidemiologia , Criança , Estudos Transversais , Feminino , Humanos , Masculino , Pandemias , Puberdade , Puberdade Precoce/epidemiologiaRESUMO
RESUMO: Objetivo: Identificar o efeito do uso de contraceptivos hormonais orais na depressão, ansiedade e qualidade de vida. Métodos: Neste estudo, utiliza-se o método transversal e a amostra foi 113 mulheres em idade reprodutiva. Para avaliação de depressão, ansiedade e qualidade de vida foram utilizados o Inventário de BECK, IDATE Traço--Estado e o SF-36, respectivamente. Para análise estatística utilizou-se o programa STATA 14.0. O nível de significância adotado foi de 5%. Resultados: Mulheres que utilizam contraceptivos tiveram idade 24,02±5,30 anos, menarca 12,23±1,40 anos e peso 58,90±10,20 kg. O não consumo de álcool e tabaco foi de 73 (64,60%) e 111(98,23%), respectivamente. Nas usuárias de contraceptivos hormonais orais combinados e não usuárias de contraceptivos hormonais orais combinados em relação ao tipo de ansiedade e nível de depressão, não houve diferença estatisticamente significante. Prevaleceram as mulheres assintomáticas em relação a depressão (não usuárias de contraceptivos hormonais orais combinados 61/82,43%) e presença de ansiedade/traço e ansiedade/estado, em ambos os grupos. A qualidade de vida não foi prejudicada pelo uso ou não dos contraceptivos hormonais orais combinados. Conclusão: O uso do Contraceptivo não está relacionado á presença de ansiedade, depressão e alteração de qualidade de vida. (AU)
ABSTRACT: Objective: Identify the effect of oral hormonal contraceptive use on depression, anxiety, and quality of life.Methods: A cross-sectional study method was used and the sample was 113 women on reproductive age. Depression,anxiety, and QoL were assessed by the BECK Inventory, the State-Trait IDATE, and the SF-36, respectively. For the statistical analysis, the STATA 14.0 program was used. The level of significance was 5%. Results: Women who use oral contraceptives have age 24,02 ± 5,30 years, menarche 12,23±1,40 years, and weight 58.9 kg. Nonconsumption of alcohol and tobacco prevailed, respectively, with 73 (64.60%) and 111 (98.23%). Concerning the use of combined oral hormonal contraceptives and without the use of COHC in relation to the type of anxiety and level of depression, there was no statistically significant difference between them. Asymptomatic women prevailedin relation to depression (without the use of combined oral hormonal contraceptives 61/82.43%) and presence of anxiety/trait and anxiety/status in both groups. QoL was not impaired by the use of combined oral hormonal contraceptives or not. Conclusion: Contraceptive use is not related to the presence of anxiety, depression, and quality of life alteration. (AU)
